Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth <b> <i>in Vitro</i> </b> and <b> <i>in Vivo</i> </b>Barbara A. Spruce, Suzanne A. Eccles, Lorna Campbell et al.|Cancer Research|2004Cited by 165
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant CancersTimothy A. Yap, Johann S. de Bono, Rebecca Kristeleit et al.|Cancer Discovery|2020Cited by 134
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Isaac García-Murillas et al.|Cancer Discovery|2020Cited by 67